En un principio el Selinexor es parecido al aplidin de Pharmamar..aprobado para el melanoma y se está probando en fase 2..a pharmamar solo le han dejado en fase 1 “In my laboratory, we have now used two different approaches to investigate selinexor’s ability to inhibit the viral propagation of the SARS-CoV-2 virus in Vero cells, which are monkey cells commonly used in modeling human viral infections. In our first experiment, with the assistance of Jackelyn Murray in my lab, we demonstrated that selinexor inhibited the production of new virus by 90% at a low concentration (100 nM) from cells that were already infected with SARS-CoV2. This is very exciting as low oral doses of selinexor are expected to deliver levels over 300 nM. In the second experiment, we showed that even lower levels of selinexor, only 10nM, could reduce the ability of the virus to infect new cells by about 99%. I am highly encouraged by these results and thrilled to see how quickly Karyopharm is able to test these scientific findings in patients so dramatically impacted by the current COVID-19 pandemic,” said Ralph Tripp, PhD, a Georgia Research Alliance Eminent Scholar and Professor in the Department of Infectious Diseases in the College of Veterinary Medicine at the University of Georgia.”Curiosamente también tiene capacidad antiinflamatoria “compounds, including selinexor, have demonstrated potent anti-inflammatory activity through the inhibition of Nuclear Factor kB (NF-kB), leading to reductions in cytokines such as IL6, IL1, IFNg and others in a variety of model”Sin embargo, están probando una dosis muy pequeña y tiene importantes efectos secundarios como le pasa a la aplidin de pharmamar. Y como le pasa a pharmamar hay muchas dudas sobre su seguridad“There are mountain ranges with less jagged curves than Karyopharm’s stock $KPTI.Over the last year, the biotech has risen and cratered and risen again as a debate over whether its lead drug is safe — or even works — played out in public FDA reviews and advisory committee hearings. But after a skeptical internal review from the agency noted previously undisclosed trial deaths and a solid majority of outside advisors voted to reject the drug,...”